Citigroup
VKTX icon

Citigroup’s Viking Therapeutics VKTX Stock Holding History

Citigroup’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,200
Closed -$57K – 7459
2020
Q4 		$57K Buy
10,200
+300
+3% +$1.82K ﹤0.01% 5950
2020
Q3 		$58K Sell
9,900
-1,500
-13% -$10.3K ﹤0.01% 5504
2020
Q2 		$82K Buy
11,400
+1,500
+15% +$9.96K ﹤0.01% 5743
2020
Q1 		$46K Sell
9,900
-23,300
-70% -$143K ﹤0.01% 6043
2019
Q4 		$266K Sell
33,200
-2,800
-8% -$20.4K ﹤0.01% 4944
2019
Q3 		$248K Sell
36,000
-15,500
-30% -$115K ﹤0.01% 4969
2019
Q2 		$427K Buy
51,500
+13,600
+36% +$116K ﹤0.01% 4574
2019
Q1 		$377K Buy
37,900
+13,600
+56% +$114K ﹤0.01% 4489
2018
Q4 		$186K Buy
24,300
+2,300
+10% +$27.5K ﹤0.01% 5086
2018
Q3 		$383K Buy
+22,000
New +$262K ﹤0.01% 4594

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Citigroup's VKTX Position: Q2 2026 in Review

Citigroup increased its Viking Therapeutics (VKTX) stake by 168% in Q2 2026, buying an estimated $5.94M and bringing the position to 293,126 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

Citigroup first reported a position in VKTX in Q1 2016 and has held it in 34 quarters since. The position peaked at $22.9M in Q2 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Citigroup held 293,126 shares of Viking Therapeutics worth $11.4M as of Q2 2026.
  • Citigroup bought 183,831 Viking Therapeutics shares in Q2 2026, an estimated $5.94M.
  • Viking Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1507 holding.
  • Citigroup first reported a position in Viking Therapeutics in Q1 2016 and has held it in 34 quarters since.
  • Citigroup's Viking Therapeutics position peaked at $22.9M in Q2 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.